Industry insiders often have perspectives that are invaluable for investors to learn. In that vein, 's (NASDAQ: AZN) CEO, Pascal Soriot, recently made some interesting remarks during the company's second-quarter earnings call with analysts.

Soriot's view has major implications for how investors should approach stocks like AstraZeneca, as well as weight loss drug leaders like Novo Nordisk and Eli Lilly -- not to mention biotechs aiming to enter the space, like Viking Therapeutics, Structure Therapeutics, and Zealand Pharma.

So let's examine what he had to say, and what it implies about how to invest in this space.

Continue reading

Source Fool.com